References
- KlinglerHCKlinglerPJMartinJKJrSmallridgeRCSmithSLHinderRAPheochromocytomaUrology20015761025103211377298
- ZarnegarRKebebewEDuhQYClarkOHMalignant pheochromocytomaSurg Oncol Clin N Am200615355557116882497
- CarrasquilloJAPandit-TaskarNChenCCI-131 metaiodobenzylguanidine therapy of pheochromocytoma and paragangliomaSemin Nucl Med201646320321427067501
- FishbeinLPheochromocytoma and paraganglioma: genetics, diagnosis, and treatmentHematol Oncol Clin North Am201630113515026614373
- LoweryAJWalshSMcDermottEWPrichardRSMolecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomasOncologist201318439140723576482
- MohammedAAEl-ShentenawyAMSherisherMAEl-KhatibHMTarget therapy in metastatic pheochromocytoma: current perspectives and controversiesOncol Rev20148224925992237
- BauerSYuLKDemetriGDFletcherJAHeat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumorCancer Res200666189153916116982758
- BanerjiUHeat shock protein 90 as a drug target: some like it hotClin Cancer Res200915191419118027
- MontemurroMBauerSTreatment of gastrointestinal stromal tumor after imatinib and sunitinibCurr Opin Oncol201123436737221519258
- XuYQiYRuiWExpression and diagnostic relevance of heat shock protein 90 and signal transducer and activator of transcription 3 in malignant pheochromocytomaJ Clin Pathol201366428629023322822
- BoltzeCMundschenkJUngerNExpression profile of the telomeric complex discriminates between benign and malignant pheochromocytomaJ Clin Endocrinol Metab20038894280428612970299
- PiperPWMillsonSHMechanisms of resistance to HSP90 inhibitor drugs: a complex mosaic emergesPharmaceuticals (Basel)20114111400142227721330
- JaroszDHSP90: a global regulator of the genotype-to-phenotype map in cancersAdv Cancer Res201612922524726916007
- LeeKHLeeJHHanSWAntitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteinsCancer Sci201110271388139521453385
- GasparNSharpSYPaceySAcquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cellsCancer Res20096951966197519244114
- NöltingSGarciaEAlusiGCombined blockade of signalling pathways shows marked anti-tumour potential in pheochromocytoma cell linesJ Mol Endocrinol2012492799622715163
- CarracedoAMaLTeruya-FeldsteinJInhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancerJ Clin Invest200811893065307418725988